Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, January 4, 2016

Game-Changers in 2015: Endovascular Tx for Stroke

I call BULLSHIT. The game changer is that nothing has been done to solve anything to do with the neuronal cascade of death. Once again 'happy talk' pervades stroke instead of realism.
http://www.medpagetoday.com/Cardiology/Strokes/55483?xid=nl_mpt_DHE_2016-01-04&eun=g424561d0r
Endovascular therapy was a "game-changer" in stroke in 2015, leading specialists told MedPage Today.
Beginning in January with the MR CLEAN trial, through June with the publication of SWIFT PRIME and REVASCAT, multiple studies demonstrated that thrombectomy outperformed tPA alone in boosting 90-day functional independence by 13.5% to 31%.
An editorial in the New England Journal of Medicine called it a "sea change" and added, "It's about time."
In response to the question of what was the biggest clinical advance of 2015, six of seven leading stroke specialists agreed: endovascular therapy.
The response on stroke came from a survey of 55 neurologists, asking their opinions on the biggest clinical advance in their subspecialty. The "game-changers" selected in five major subspecialties were:
1. MS: Ocrelizumab results in ORATORIO and OPERA I and II
2. Stroke: Thrombectomy for acute ischemic stroke
3. Parkinson's disease: New therapies for delivering carbidopa/levodopa
4. Sleep: SERVE-HF trial showing adaptive servoventilation increased mortality
5. Alzheimer's disease: No single clinical advance stood out
Questions over optimal stroke therapy had persisted since three trials in 2013 suggested endovascular therapy was no more effective than intravenous tPA alone. But all that changed this year.
"Mechanical thrombectomy for acute ischemic stroke is a once-in-a-generation breakthrough in care," said Jeffrey L. Saver, MD, director, UCLA Comprehensive Stroke Center and first author of the SWIFT-PRIME trial.
"More patients will be going home free of disability after large ischemic strokes than ever before," said Pat Lyden, MD, chair of neurology and director of the Cedars-Sinai Stroke Center in Los Angeles.
And Joseph Broderick MD, director of the University of Cincinnati Neuroscience Institute, labeled it the "biggest change in acute stroke therapy since tPA approval for stroke in 1996."
The breakthrough of thrombectomy came about, experts say, because of several factors: improvement in technology of the stent receiver device which can achieve more complete recanalization; improved workflow efficiencies producing faster door-to-treatment times; and change in neuroimaging criteria for identifying large vessel occlusions.
The positive results of these trials is now leading to new questions about ways to improve treatment.
In imaging, said Wayne Clark, MD, director of the Oregon Health & Science University Stroke Center in Portland, "Advances in imaging technology now allow us to identify patient's that can still benefit from thrombectomy even if they are past eight hours due to 'waking up' with their symptoms."
Marilyn Rymer, MD, vice president for Neuroscience, University of Kansas Medical Center, believes the field now faces a number of important questions about imaging: "Can (we) select cases likely to have a good outcome with EVT based on imaging criteria and potentially expand the number of eligible cases well beyond the usual time window? What imaging criteria should be used? Are imaging criteria the best way to select appropriate cases for EVT?"
Also, access to endovascular therapy is currently a limiting factor. It "needs to be given in advanced centers with clinical expertise and the necessary acute and post-treatment support structure," said Larry B. Goldstein, MD, Ruth L. Works professor and chair of neurology, University of Kentucky. But these patients cannot be easily transported to the centers. "It remains to be determined how best to integrate this approach into overall systems of care on a regional and state-wide basis," he said.
Lyden says possible solutions are novel approaches for triage in the field including "new paramedic tools; in-ambulance telemedicine; or even the mobile stroke units that contain a CT scanner on the ambulance."

No comments:

Post a Comment